Buy Divi's Laboratories, target price Rs 3900: Motilal Oswal

Divi's Laboratories Ltd., incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 85938.82 Crore) operating in Pharmaceuticals sector.

BCCL
Promoters held 52 per cent stake in the company as of Sept 30, 2020, while FIIs held 18.3 per cent, DIIs 18.8 per cent and public and others 11 per cent.
Motilal Oswal has given a buy rating to Divi's Laboratories with a target price of Rs 3900. The share price moved up by 4.23 per cent from its previous close of Rs 3237.70. The stock’s last traded price is Rs 3374.70.

Divi's Laboratories Ltd., incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 85938.82 Crore) operating in Pharmaceuticals sector.

Financials
For the quarter ended 30-06-2020, the company reported a Consolidated sales of Rs 1730.47 Crore, up 24.52 % from last quarter Sales of Rs 1389.71 Crore and up 48.81 % from last year same quarter Sales of Rs 1162.88 Crore Company reported net profit after tax of Rs 492.06 Crore in latest quarter.

divi

Investment Rationale
The brokerage values DIVI at 36x 12M forward earnings to arrive at TP of INR3,900. It reiterates BUY, supported by promising demand prospects and multiple levers – chemistry skill sets, efficient manufacturing capabilities, and considerable scale of operations to gain market share in focus products.

Promoter/FII Holdings
Promoters held 52 per cent stake in the company as of Sept 30, 2020, while FIIs held 18.3 per cent, DIIs 18.8 per cent and public and others 11 per cent.
ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+